IP Library Granted Patent US 7,217,531
Granted Patent B2
US 7,217,531 · App. 11/214,234 · Granted May 15, 2007

Multiplex analysis using membrane-bound sensitizers

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,217,531
App. No.
11/214,234
Granted
May 15, 2007
Kind
B2
Abstract

The present invention is directed to methods and compositions for determining the presence, absence, and/or amounts of one or more membrane-associated analytes in a sample. In accordance with the invention, binding compounds derivatized with releasable molecular tags specifically bind to selected membrane-associated analytes, after which the molecular tags are released upon activation of cleavage moieties, or sensitizers, anchored in the same membrane as the membrane-associated analytes. The released molecular tags are then identified by their distinct separation and detection characteristics.

Claims (9)

1. A composition for determining the presence or absence of one or more membrane-associated analytes, the composition comprising:

a sensitizer-treated membrane containing one or more membrane associated analytes, the sensitizer-treated membrane comprising a cell surface membrane having photosensitizers attached, the photosensitizers each having a lipophilic moiety for anchoring the photosensitizers in the cell surface membrane; and

one or more binding compounds, such that there is at least one binding compound specific for each of the one or more membrane-associated analytes, each binding compound having one or more molecular tags, each molecular tag being attached by a cleavable linkage, and the molecular tags of each binding compound being distinguishable from those of every other binding compound by one or more physical and/or optical characteristics;

wherein at least one binding compound of the plurality is specifically bound to at least one membrane-associated analyte.

2. The composition of claim 1 wherein said one or more membrane-associated analytes are selected from the group consisting of G-protein coupled receptors “GPCRs.”

3. The composition of claim 1 wherein said one or more binding compounds each comprises an antibody composition.

4. The composition of claim 3 wherein said antibody composition is a monoclonal antibody or a polyclonal antibody composition.

5. The composition according to claims 1 , 2 , 3 , or 4 wherein said one or more binding compounds is a plurality of said binding compounds in the range of from 2 to 50 and wherein said one or more physical characteristics is electrophoretic mobility.

6. The composition of claim 5 wherein said molecular tags upon cleavage from different said binding compounds form distinct peaks in an electropherogram.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Aug 27, 2009
From: GE BUSINESS FINANCIAL SERVICES INC., FORMERLY MERRILL LYNCH BUSINESS FINANCIAL SERVICES INC.
To: MONOGRAM BIOSCIENCES, INC.
Reel/Frame 023148/0723 →
SECURITY AGREEMENT Recorded Oct 4, 2006
From: MONOGRAM BIOSCIENCES, INC.
To: MERRILL LYNCH CAPITAL, A DIVISION OF MERRILL LYNCH BUSINESS FINANCIAL SERVICES INC.
Reel/Frame 018338/0818 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2005
From: SINGH, SHARAT; CHAN-HUI, PO-YING; KIRAKOSSIAN, HRAIR
To: MONOGRAM BIOSCIENCES, INC.
Reel/Frame 017217/0610 →